Suppr超能文献

症状性心房颤动导管消融术前阻塞性睡眠呼吸暂停筛查和治疗的成本效益

Cost-Effectiveness of Obstructive Sleep Apnea Screening and Treatment Before Catheter Ablation for Symptomatic Atrial Fibrillation.

作者信息

Kawakami Hiroshi, Saito Makoto, Kodera Satoshi, Fujii Akira, Nagai Takayuki, Uetani Teruyoshi, Tanno Sakurako, Oka Yasunori, Ikeda Shuntaro, Komuro Issei, Marwick Thomas H, Yamaguchi Osamu

机构信息

Department of Cardiology, Pulmonology, Hypertension and Nephrology, Ehime University Graduate School of Medicine Toon Japan.

Department of Cardiac Imaging, Baker Heart and Diabetes Institute Melbourne Australia.

出版信息

Circ Rep. 2020 Aug 27;2(9):507-516. doi: 10.1253/circrep.CR-20-0074.

Abstract

Although management of obstructive sleep apnea (OSA) has been recommended to improve outcomes of catheter ablation (CA) in patients with symptomatic atrial fibrillation (AF), the most cost-effective way of preprocedural OSA screening is undetermined. This study assessed the cost-effectiveness of OSA management before CA for symptomatic AF. A Markov model was developed to assess the cost-effectiveness of 3 OSA detection strategies before CA: no screening; Type 3 portable monitor (PM)-guided screening; and polysomnography (PSG)-guided screening. The target population consisted of a hypothetical cohort of patients aged 65 years with symptomatic AF, with 50% prevalence of OSA. We used a 5-year horizon, with sensitivity analyses for significant variables and scenario analyses for lower and higher OSA prevalence (30% and 70%, respectively). In the base-case, both types of OSA screening were dominant (less costly and more effective) relative to no screening. Although PSG-guided management was more effective than PM-guided management, it was more costly and therefore did not show clear benefit. These findings were replicated in cohorts with lower and higher OSA risks. OSA screening before CA is cost-effective in patients with symptomatic AF, with PM screening being the most cost-effective. Physicians should consider OSA management using this simple tool in the decision making for treatment of symptomatic AF.

摘要

尽管推荐对阻塞性睡眠呼吸暂停(OSA)进行管理以改善症状性心房颤动(AF)患者的导管消融(CA)结果,但术前OSA筛查的最具成本效益的方式尚未确定。本研究评估了CA治疗症状性AF前OSA管理的成本效益。构建了一个马尔可夫模型来评估CA术前三种OSA检测策略的成本效益:不筛查;3型便携式监测仪(PM)引导下的筛查;以及多导睡眠图(PSG)引导下的筛查。目标人群为假设的65岁症状性AF患者队列,OSA患病率为50%。我们采用5年时间范围,对重要变量进行敏感性分析,对较低和较高的OSA患病率(分别为30%和70%)进行情景分析。在基础病例中,相对于不筛查,两种类型的OSA筛查均占优势(成本更低且更有效)。虽然PSG引导下的管理比PM引导下的管理更有效,但成本更高,因此未显示出明显益处。这些结果在OSA风险较低和较高的队列中得到了重复。CA术前进行OSA筛查对症状性AF患者具有成本效益,其中PM筛查最具成本效益。医生在决定治疗症状性AF时应考虑使用这种简单工具进行OSA管理。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验